David Paul Fredrickson - 17 Jun 2025 Form 3 Insider Report for Caris Life Sciences, Inc.

Role
Director
Signature
/s/ J. Russel Denton, Attorney-in-Fact
Issuer symbol
CAI on Nasdaq
Transactions as of
17 Jun 2025
Net transactions value
$0
Form type
3
Filing time
17 Jun 2025, 21:34:11 UTC
Next filing
27 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Fredrickson David Paul Director C/O CARIS LIFE SCIENCES, INC., 750 W. JOHN CARPENTER FREEWAY, SUITE 800, IRVING /s/ J. Russel Denton, Attorney-in-Fact 17 Jun 2025 0002071948

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding CAI Common Stock 16,129 17 Jun 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CAI Stock Option 17 Jun 2025 Common Stock 75,000 $19.44 Direct F2
holding CAI Stock Option 17 Jun 2025 Common Stock 2,500 $18.60 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 16,129 shares of Common Stock underlying restricted stock units which vest in accordance with the applicable grant agreement.
F2 The stock option vests in five substantially equal annual installments beginning on August 14, 2025.
F3 The stock option is fully vested and exercisable.

Remarks:

Exhibit 24 - Power of Attorney.